drugset / Trial / NCT00686868
Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose escalation/de-escalation phase to investigate the minimal efficacious dose based on PD markers with an acceptable safety profile.
Timeline
- Start
- 2008-06-13
- Primary completion
- 2011-03-11
- Completion
- 2011-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ofatumumab | Monoclonal antibody | 0.3 mg | Subcutaneous |
| Subject | Ofatumumab | Monoclonal antibody | 3 mg | Subcutaneous |
| Subject | Ofatumumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Ofatumumab | Monoclonal antibody | 60 mg | Subcutaneous |
| Subject | Ofatumumab | Monoclonal antibody | 100 mg | Subcutaneous |